AstraZeneca plc (LON:AZN) had its target price cut by Bryan, Garnier & Co from GBX 5,400 ($70.49) to GBX 5,220 ($68.14) in a research report issued on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Bryan, Garnier & Co’s price objective would suggest a potential upside of 3.53% from the stock’s previous close.
AZN has been the subject of a number of other reports. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,800 ($75.71) price target on shares of AstraZeneca plc in a report on Friday, July 29th. Jefferies Group reissued a “hold” rating on shares of AstraZeneca plc in a report on Monday, June 6th. Berenberg Bank set a GBX 5,550 ($72.44) price target on shares of AstraZeneca plc and gave the company a “buy” rating in a report on Thursday, August 25th. HSBC reissued a “hold” rating and issued a GBX 4,240 ($55.35) price target on shares of AstraZeneca plc in a report on Friday, June 17th. Finally, Citigroup Inc. reissued a “buy” rating on shares of AstraZeneca plc in a report on Wednesday, July 27th. Five research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) opened at 5042.00 on Tuesday. The firm’s market capitalization is GBX 63.78 billion. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00. The company has a 50 day moving average of GBX 5,006.61 and a 200 day moving average of GBX 4,427.08.
The business also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date was Thursday, August 11th. This represents a yield of 1.37%.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.